By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Ohio State University and Indiana University will use a $9 million award from the National Cancer Institute to continue studies on cancer genes and the epigenetic agents that mask their expression.

Over the next five years, researchers from both universities will study epigenetic changes in prostate, breast, and ovarian cancer cells that cause resistance to hormonal therapy or traditional chemotherapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."